Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Looking To Tap Into Asia’s Emerging Oncology Market

This article was originally published in PharmAsia News

Executive Summary

Looking to increase global market share, Pfizer has established a business unit devoted to oncology within its worldwide pharmaceutical group, in part, to strengthen research investment on cancers common in Asia, including liver, esophagus and nasopharynx

You may also be interested in...



Pfizer Restructures for a More Flexible Future

In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.

Pharma Business Structure, M&As Evolving To Create Smaller Cross-Functional Units

TOKYO - Strategies for mergers and acquisitions in the global pharmaceutical market are changing from marriages of equals to alliances and buyouts with biotechs, which often create cross-functional smaller units within big pharmas, said Hiroshi Nakamura, professor at the Keio University Business School

Pharma Business Structure, M&As Evolving To Create Smaller Cross-Functional Units

TOKYO - Strategies for mergers and acquisitions in the global pharmaceutical market are changing from marriages of equals to alliances and buyouts with biotechs, which often create cross-functional smaller units within big pharmas, said Hiroshi Nakamura, professor at the Keio University Business School

Related Content

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel